Ret Kidney

The dosage of Calcium Sulfate Anhydrous for adults is highly individualized based on the specific indication being treated and the patient's overall health status. For general nutritional supplementation and Vitamin C-related support, the standard dose typically ranges from 500 mg to 1500 mg daily, often divided into two or three doses to maximize absorption. When utilized for its adrenergic or stimulant properties, healthcare providers may initiate therapy at lower doses, such as 100 mg to 250 mg, and titrate upward based on clinical response and cardiovascular tolerance. For the dissolution of renal calculi, doses are often adjusted based on urinary pH monitoring, with typical ranges between 1000 mg and 2000 mg per day.

Calcium Sulfate Anhydrous must be used with extreme caution in the pediatric population. Dosage is usually calculated based on weight (mg/kg) or body surface area. For children aged 6 to 12 years, the typical supplemental dose is 250 mg to 500 mg daily. For children under 6 years of age, safety and efficacy have not been firmly established for all indications, and use should be restricted to specialized clinical settings under the direction of a pediatric specialist. Pediatric patients are more sensitive to the adrenergic and CNS stimulant effects of the drug, necessitating frequent monitoring of heart rate and neurological status.

Renal Impairment

In patients with mild to moderate renal impairment (CrCl 30-60 mL/min), the dose of Calcium Sulfate Anhydrous should be reduced by approximately 25-50% to prevent the accumulation of calcium and sulfate ions, which can lead to systemic toxicity. In patients with severe renal impairment or end-stage renal disease (ESRD), the use of this agent is generally contraindicated unless the benefits significantly outweigh the risks of hypercalcemia and metabolic acidosis.

Hepatic Impairment

While Calcium Sulfate Anhydrous is not primarily metabolized by the liver, patients with hepatic impairment may have altered protein binding (due to hypoalbuminemia) and fluid balance issues. Dosage adjustments are not typically required based on hepatic function alone, but close monitoring of ionized calcium levels is recommended in patients with Child-Pugh Class B or C cirrhosis.

Elderly Patients

Geriatric patients often have reduced renal clearance and a higher prevalence of cardiovascular comorbidities. It is recommended to start at the lowest end of the dosing range (e.g., 250 mg once daily) and monitor for signs of CNS overstimulation or cardiac arrhythmias. The risk of constipation and fecal impaction is also higher in this population.

Calcium Sulfate Anhydrous should be taken exactly as prescribed by a healthcare professional. For optimal absorption, oral forms should be taken with a full glass of water (8 oz). While it can be taken with or without food, taking it with a meal may reduce the risk of gastrointestinal upset. However, avoid taking it simultaneously with high-fiber meals or dairy products, as these can interfere with calcium absorption. If using the anhydrous powder, it must be thoroughly mixed with the recommended volume of liquid and consumed immediately. Do not crush or chew extended-release formulations if they are provided in that form. Storage should be in a cool, dry place (15°C to 30°C), away from excessive moisture, as the anhydrous form can readily absorb water from the atmosphere, which may degrade the product.

If a dose of Calcium Sulfate Anhydrous is missed, it should be taken as soon as the patient remembers. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. Patients should never "double up" or take two doses at once to make up for a missed one, as this significantly increases the risk of acute toxicity and electrolyte imbalance.

Signs of an overdose of Calcium Sulfate Anhydrous include severe nausea, vomiting, confusion, lethargy, muscle weakness, and cardiac arrhythmias (irregular heartbeats). In extreme cases, overdose can lead to a "calcium storm," characterized by acute hypercalcemia, hypertensive crisis (due to adrenergic effects), and renal failure. If an overdose is suspected, emergency medical services should be contacted immediately. Treatment typically involves aggressive intravenous hydration with isotonic saline, loop diuretics to enhance calcium excretion, and supportive care for cardiovascular stability.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Regular laboratory monitoring may be required to ensure your levels remain within a safe therapeutic range.

The most frequently reported side effects associated with Calcium Sulfate Anhydrous are gastrointestinal in nature. Patients often experience constipation, which can range from mild to severe. This occurs because calcium ions can slow the transit time of the intestines. Other common effects include abdominal bloating, gas (flatulence), and a sense of fullness. Some patients may also report a metallic taste in the mouth or mild nausea shortly after administration. These symptoms typically diminish as the body adjusts to the medication, but increasing fluid intake and dietary fiber can help mitigate gastrointestinal distress.

Less common side effects involve the central nervous and cardiovascular systems, particularly due to the drug's stimulant and adrenergic properties. These may include:

• Insomnia: Difficulty falling or staying asleep, often linked to the CNS stimulant effect.
• Palpitations: A sensation of a racing or fluttering heart.
• Mild Hypertension: A slight increase in blood pressure.
• Anxiety or Jitteriness: A feeling of restlessness or nervous energy.
• Dry Mouth (Xerostomia): Reduced salivary flow.
• Polyuria: Increased frequency of urination, especially if the drug is acting as a calculi dissolution agent.

Rare but documented side effects include:

• Hypercalcemia: Excessively high levels of calcium in the blood, leading to fatigue and bone pain.
• Milk-Alkali Syndrome: A triad of hypercalcemia, metabolic alkalosis, and renal failure, usually seen with high-dose calcium intake.
• Confusion or Hallucinations: Particularly in elderly patients or those with pre-existing psychiatric conditions.
• Severe Dermatological Reactions: Including pruritus (itching) or urticaria (hives).
• Nephrolithiasis: Paradoxically, the formation of new kidney stones in susceptible individuals.

> Warning: Stop taking Calcium Sulfate Anhydrous and call your doctor immediately if you experience any of these serious adverse events.

1. 1Anaphylaxis: Symptoms include swelling of the face, lips, or tongue, difficulty breathing, and a rapid drop in blood pressure. This is a life-threatening allergic reaction.
2. 2Cardiac Arrhythmias: Feeling like your heart is skipping beats, pounding, or beating too fast (tachycardia). Given its Adrenergic Agonist [EPC] status, this can lead to serious cardiac instability.
3. 3Severe Hypertensive Crisis: Sudden, severe headache, blurred vision, and chest pain.
4. 4Neuromuscular Blockade: Unexpected muscle weakness, drooping eyelids, or difficulty swallowing, related to its role as an Acetylcholine Release Inhibitor.
5. 5Acute Renal Failure: Significant decrease in urine output, swelling in the legs and ankles, and shortness of breath.

Prolonged use of Calcium Sulfate Anhydrous can lead to the calcification of soft tissues, including the blood vessels and heart valves, especially in patients with underlying renal issues. Chronic over-supplementation may also interfere with the absorption of other essential minerals, such as magnesium and zinc, leading to secondary deficiencies. There is also a risk of developing a psychological or physiological dependence on the stimulant effects of the drug if used chronically at high doses.

No FDA black box warnings have been issued for Calcium Sulfate Anhydrous as of 2026. However, clinical guidelines emphasize that it should not be used in patients with pre-existing hypercalcemia or severe renal impairment due to the risk of life-threatening electrolyte imbalances.

Report any unusual symptoms to your healthcare provider. Early detection of side effects is crucial for adjusting the therapeutic regimen and preventing long-term complications.

Calcium Sulfate Anhydrous is a potent pharmacological agent with systemic effects across multiple organ systems. It is not a simple mineral supplement; its classification as an Adrenergic Agonist and CNS Stimulant necessitates careful patient screening. Patients with a history of cardiovascular disease, including hypertension, arrhythmias, or a recent myocardial infarction, must be monitored closely, as the drug can exacerbate these conditions. Furthermore, the anhydrous nature of the compound means it is highly hygroscopic; patients must be cautioned against using product that appears damp or clumped, as the chemical potency may be altered.

No FDA black box warnings for Calcium Sulfate Anhydrous. While the drug is generally considered safe when used as directed, the absence of a black box warning does not imply a lack of risk. The potential for cardiovascular and renal toxicity remains a primary clinical concern.

• Allergic Reactions / Anaphylaxis Risk: Patients with known sensitivities to sulfate compounds or specific allergenic extracts (fungal, plant, or insect) should avoid this medication. Cross-reactivity is possible.
• Cardiotoxicity: Due to its beta-adrenergic agonist activity, there is a risk of inducing or worsening supraventricular tachycardia and ventricular ectopy. Baseline and periodic EKGs may be necessary for high-risk patients.
• Nephrotoxicity: High doses can lead to hypercalciuria and the formation of calcium sulfate stones. Patients with a history of nephrolithiasis should use this drug with extreme caution.
• Gastrointestinal Obstruction: In rare cases, the anhydrous salt can form a mass (bezoar) in the stomach or intestines if not taken with sufficient water, leading to obstruction.

Healthcare providers should implement a rigorous monitoring schedule for patients on long-term Calcium Sulfate Anhydrous therapy:

1. 1Serum Electrolytes: Regular testing of serum calcium, phosphate, and magnesium levels.
2. 2Renal Function: Monitoring of Serum Creatinine and Blood Urea Nitrogen (BUN), along with calculated GFR.
3. 3Blood Pressure and Heart Rate: Routine monitoring at each clinical visit to assess the impact of adrenergic stimulation.
4. 4Urinary Calcium: 24-hour urine calcium collection may be required to assess the risk of stone formation.

Because Calcium Sulfate Anhydrous acts as a Central Nervous System Stimulant [EPC], it may cause jitteriness, anxiety, or sudden changes in focus. Conversely, in some individuals, the subsequent "crash" after the stimulant effect wears off can cause significant fatigue. Patients should determine how they react to the medication before driving or operating heavy machinery.

Alcohol consumption should be limited while taking Calcium Sulfate Anhydrous. Alcohol can exacerbate the gastrointestinal side effects and may increase the risk of dehydration, which significantly raises the risk of hypercalcemia and renal stone formation. Additionally, alcohol can have unpredictable effects on the drug's adrenergic activity, potentially leading to increased heart rate or blood pressure instability.

Calcium Sulfate Anhydrous should not be discontinued abruptly, especially if taken at high doses for its stimulant or adrenergic effects. A gradual tapering schedule, supervised by a healthcare provider, is recommended to prevent withdrawal-like symptoms such as extreme fatigue, rebound hypotension, or irritability.

> Important: Discuss all your medical conditions with your healthcare provider before starting Calcium Sulfate Anhydrous. Provide a full list of all other medications you are currently taking.

Calcium Sulfate Anhydrous must NEVER be used in combination with the following medications:

• Ceftriaxone (IV): Concurrent use can lead to the formation of life-threatening calcium-ceftriaxone precipitates in the lungs and kidneys, particularly in neonates and young children.
• Digoxin: High levels of calcium significantly increase the toxicity of digoxin, potentially leading to fatal cardiac arrhythmias. This is a critical pharmacodynamic interaction.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): Combining Calcium Sulfate Anhydrous (due to its Adrenergic Agonist properties) with MAOIs can precipitate a hypertensive crisis.

• Thiazide Diuretics (e.g., Hydrochlorothiazide): These drugs reduce renal calcium excretion, significantly increasing the risk of hypercalcemia.
• Quinolone Antibiotics (e.g., Ciprofloxacin): Calcium Sulfate Anhydrous can chelate these antibiotics in the gut, reducing their absorption and efficacy by up to 50-70%. Doses should be separated by at least 2-4 hours.
• Tetracycline Antibiotics (e.g., Doxycycline): Similar to quinolones, chelation occurs, rendering the antibiotic less effective.
• Bisphosphonates (e.g., Alendronate): Calcium interferes with the absorption of these bone-density medications. They must be taken at least 30-60 minutes before the calcium salt.

• Levothyroxine: Calcium can bind to thyroid hormones in the GI tract. Levothyroxine should be taken on an empty stomach, at least 4 hours apart from Calcium Sulfate Anhydrous.
• Iron Supplements: Calcium competes with iron for absorption. Separating doses by several hours is recommended.
• Sotalol: Calcium can decrease the plasma concentrations and clinical efficacy of this anti-arrhythmic agent.

• High-Phytate Foods: Whole grains and legumes contain phytates that bind to calcium and prevent its absorption.
• Oxalic Acid: Spinach, rhubarb, and beets contain oxalates that can form insoluble calcium oxalate, reducing bioavailability and increasing the risk of kidney stones.
• Caffeine: Excessive caffeine intake can increase the excretion of calcium and may synergize with the drug's stimulant effects, leading to excessive heart rate and anxiety.
• Dairy Products: While containing calcium, excessive dairy can lead to Milk-Alkali Syndrome when combined with high-dose Calcium Sulfate Anhydrous.

• St. John's Wort: May theoretically alter the CNS effects of the drug, though a direct CYP interaction is not expected.
• Ginkgo Biloba: May increase the risk of palpitations when combined with the adrenergic effects of Calcium Sulfate Anhydrous.
• Vitamin D Supplements: Vitamin D significantly increases the intestinal absorption of calcium. While often used together, this combination requires careful monitoring to prevent hypercalcemia.

Calcium Sulfate Anhydrous can interfere with several laboratory parameters:

• Serum Calcium: Will obviously be elevated.
• Serum Phosphate: May be decreased due to binding in the gut.
• Urinary Glucose: High calcium levels can sometimes cause false-negative results in certain glucose oxidase tests.
• Coagulation Tests: As an Anti-coagulant [EPC] in certain contexts, it may slightly prolong certain clotting times, though this is rarely clinically significant at standard doses.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the only way to prevent dangerous interactions.

Calcium Sulfate Anhydrous is strictly prohibited in the following circumstances:

1. 1Hypercalcemia: Any condition that results in baseline elevated serum calcium levels (e.g., hyperparathyroidism, sarcoidosis, or certain malignancies) is an absolute contraindication, as the drug will exacerbate this dangerous state.
2. 2Severe Renal Impairment (CrCl < 30 mL/min): The inability of the kidneys to clear sulfate and calcium ions leads to rapid systemic toxicity and the risk of soft tissue calcification.
3. 3Ventricular Fibrillation: Due to its Adrenergic Agonist and stimulant properties, it can worsen lethal cardiac arrhythmias.
4. 4Known Hypersensitivity: Any previous anaphylactic or severe allergic reaction to calcium sulfate or any component of the formulation.
5. 5Calcium Nephrolithiasis: Patients with active calcium-based kidney stones should not take this agent, as it provides the substrates necessary for stone growth.

Relative contraindications require a careful risk-benefit analysis by a physician:

• History of Peptic Ulcer Disease: Calcium salts can stimulate gastrin secretion, potentially worsening ulcers.
• Mild to Moderate Hypertension: The adrenergic effects may require an adjustment of antihypertensive medications.
• Sarcoidosis: These patients have increased sensitivity to Vitamin D and calcium, increasing the risk of hypercalcemia.
• Digitalis Therapy: Requires extremely close monitoring of calcium levels to avoid digoxin toxicity.

Patients with known allergies to other sulfate salts (such as magnesium sulfate) or those who have reacted to non-standardized food or plant allergenic extracts should be monitored for cross-sensitivity. While sulfate allergy is distinct from sulfonamide (sulfa) allergy, clinical vigilance is still advised.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney stones or heart rhythm problems, before prescribing Calcium Sulfate Anhydrous.

Calcium Sulfate Anhydrous is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, or there are no adequate and well-controlled studies in humans. However, calcium is an essential mineral during pregnancy for fetal skeletal development. The use of Calcium Sulfate Anhydrous during pregnancy should be limited to cases where the nutritional or therapeutic need clearly outweighs the potential risks of adrenergic stimulation or hypercalcemia. High doses of calcium during the third trimester may increase the risk of maternal hypertension and preeclampsia. Healthcare providers typically prefer standard calcium carbonate or citrate for routine supplementation unless the specific properties of the anhydrous sulfate form are required.

Calcium is naturally excreted in human breast milk. While supplemental Calcium Sulfate Anhydrous is generally considered compatible with breastfeeding, the potential for the drug's stimulant and adrenergic properties to affect the nursing infant must be considered. There is a theoretical risk of infant irritability or sleep disturbances if the mother is taking high doses. Monitoring the infant for these symptoms is recommended. Always consult a lactation consultant or physician before starting this medication while nursing.

As noted in the dosage section, Calcium Sulfate Anhydrous is not routinely recommended for children under the age of 6. In older children, it is used primarily for specific mineral deficiencies or in specialized orthopedic procedures. Long-term use in children requires monitoring of growth and bone age, as excessive calcium can theoretically lead to premature epiphyseal closure (stopping of bone growth). The CNS stimulant effects may also manifest more prominently as hyperactivity or behavioral changes in pediatric patients.

Patients over the age of 65 are at a significantly higher risk for adverse effects. Reduced renal function (even with a "normal" creatinine) means that calcium and sulfate ions are cleared more slowly. Geriatric patients are also more susceptible to constipation and fecal impaction. Furthermore, the risk of drug-drug interactions is much higher due to polypharmacy (taking multiple medications). Cardiovascular monitoring is paramount in this population due to the age-related decline in cardiac reserve and increased sensitivity to adrenergic agonists.

In patients with renal impairment, the balance between calcium and phosphate is easily disrupted. Calcium Sulfate Anhydrous can contribute to a high calcium-phosphate product, leading to calciphylaxis (a serious condition where calcium builds up in small blood vessels). GFR-based dosing is mandatory. For patients on hemodialysis, the calcium content of the dialysate must be adjusted if the patient is taking this medication to avoid acute hypercalcemia during treatment.

While the liver is not the primary site of clearance, hepatic impairment can lead to complex changes in mineral metabolism. Patients with chronic liver disease may have underlying bone disease (hepatic osteodystrophy) and may require calcium, but the use of the anhydrous sulfate form must be balanced against the risk of metabolic acidosis, which can be poorly tolerated in patients with advanced cirrhosis.

> Important: Special populations require individualized medical assessment. Never share this medication with others, especially those in these high-risk categories.

Calcium Sulfate Anhydrous operates through several distinct molecular pathways. As an Adrenergic Agonist, it interacts with alpha-1, beta-1, and beta-2 adrenergic receptors. The anhydrous calcium ions act as secondary messengers; upon entering the cell through voltage-gated calcium channels, they trigger the release of intracellular calcium stores from the sarcoplasmic reticulum. This increase in cytosolic calcium promotes actomyosin cross-bridging in muscle cells and enhances the exocytosis of neurotransmitter vesicles.

In its role as an Acetylcholine Release Inhibitor, high local concentrations of calcium ions can paradoxically inhibit the release of acetylcholine at the presynaptic terminal through a feedback inhibition mechanism, providing its neuromuscular blocking properties. Its Acidifying Activity stems from the sulfate moiety, which, upon dissociation, can contribute to a slight decrease in systemic and urinary pH, facilitating the dissolution of alkaline-based calculi.

The pharmacodynamic effects of Calcium Sulfate Anhydrous are dose-dependent. Low doses primarily affect mineral homeostasis and provide nutritional support. Moderate doses begin to manifest adrenergic effects, such as increased heart rate and bronchodilation. High doses or rapid intravenous administration can lead to significant neuromuscular blockade and profound changes in cardiac conduction. The onset of action for oral formulations is typically 30-60 minutes, with peak effects occurring at 2 hours. The duration of the adrenergic effect is relatively short (4-6 hours), while the impact on bone mineral density is only observed after months of consistent use.

| Parameter | Value |

|---|---|

| Bioavailability | 25% - 35% (Oral) |

| Protein Binding | 40% - 45% (Primarily Albumin) |

| Half-life | 1 - 2 hours (Ionized Calcium phase) |

| Tmax | 2.0 - 3.5 hours |

| Metabolism | Non-enzymatic; regulated by PTH/Calcitonin |

| Excretion | Renal (20%), Fecal (80% unabsorbed) |

• Molecular Formula: CaSO4
• Molecular Weight: 136.14 g/mol
• Solubility: Slightly soluble in water (approx. 0.2 g/100 mL at 25°C); solubility increases in acidic environments.
• Structure: Anhydrous calcium sulfate exists in a rhombic or monoclinic crystalline structure. Unlike the dihydrate (CaSO4·2H2O), it lacks the water molecules that provide the softer, more soluble characteristic of gypsum.

Calcium Sulfate Anhydrous is a unique compound that bridges several therapeutic classes. It is primarily categorized as a Vitamin C [EPC] due to its role in supporting ascorbate-mediated collagen synthesis. It is also a member of the Adrenergic Agonist and Methylxanthine classes, sharing functional similarities with drugs like ephedrine and theophylline. In the realm of surgical materials, it is classified as a Bone Void Filler and Calculi Dissolution Agent.